EXEL logo

Exelixis (EXEL)

Profile

Full Name

Exelixis, Inc.

Ticker Symbol

EXEL

Exchange

NASDAQ

Sector

Healthcare

Industry

Biotechnology

Country

United States

IPO

April 17, 2000

Indexes

Not included

Website

http://www.exelixis.com

Employees

1147

Key Details

Price

$36.40(-0.38%)

Market cap

Last Dividend

-

TTM Dividend yield

-

Annual revenue

$2.17B(+18.49% YoY)

Annual EPS

$1.76(+170.77% YoY)

PE ratio

20.56

Next earnings date

Apr 30, 2025

Next ex-dividend date

N/A

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Current Price

$36.40
EXEL price is $36.40

30-Day Relative Volume

1.01
EXEL 30-day relative volume is 1.01

Price Performance

Price Today change

-0.38%
EXEL price is down -0.38% today

Price YTD change

+9.31%
EXEL price is up +9.31% since January 1st

Price 1-year change

+59.51%
EXEL price is up +59.51% year-on-year

Price 3-year change

+57.64%
EXEL price is up +57.64% over the past 3 years

Price Range

Price All-time high

$50.50
EXEL price is currently -27.92% below its historical high of $50.50

Price 3-year low

$14.87
EXEL price is currently +144.79% above its 3-year low

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Market cap

$10.19B
EXEL market capitalization is $10.19 billion

Market cap 3-year change

+37.76%
EXEL market capitalization is up +37.76% over the past 3 years

Market cap All-time high

$11.01B
EXEL market capitalization is currently -7.50% below its historical high of $11.01 billion

Market cap sector rank

92.85%
EXEL market capitalization is higher than 92.85% of companies in Healthcare sector

Shares Outstanding

Shares Outstanding 1-Year Change

-5.06%
EXEL shares outstanding is down -5.06% year-on-year

Shares Outstanding 3-Year Change

-12.61%
EXEL shares outstanding is down -12.61% over the past 3 years

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Beta

0.40
EXEL beta is 0.40

200-day SMA

$31.09
EXEL price is currently +17.07% above its 200-day simple moving average

50-day SMA

$36.18
EXEL price is currently +0.60% above its 50-day simple moving average

RSI

52.65
EXEL 14-day relative strength index is 52.65

Volume

1.01
EXEL 30-day relative volume is 1.01

ATR

$1.42
EXEL average true range is $1.42

10-day Historical Volatility

45.31%
EXEL 10-day historical volatility is 45.31%

Dividend

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Revenue

$2.17B
EXEL annual revenue is $2.17 billion

Revenue Analysts estimate

$2.25B
EXEL annual revenue is currently -3.75% lower than the consensus analysts' forecast

Revenue 1-year change

+18.49%
EXEL annual revenue is up +18.49% year-on-year

Revenue Sector rank

85.7%
EXEL annual revenue is higher than 85.7% of companies in Healthcare sector

EPS

EPS

$1.76
EXEL annual earnings per share is $1.76

EPS Analysts estimate

$2.30
EXEL annual earnings per share is currently -23.42% lower than the consensus analysts' forecast

EPS 1-year change

+170.77%
EXEL annual earnings per share is up +170.77% year-on-year

EPS Sector rank

91.63%
EXEL annual earnings per share is higher than 91.63% of companies in Healthcare sector

Profit

Gross profit

$2.09B
EXEL annual gross profit is $2.09 billion

Gross margin

96.49%
EXEL annual gross profit margin is 96.49%

Operating profit

$689.95M
EXEL annual operating income is $689.95 million

Operating margin

31.81%
EXEL annual operating profit margin is 31.81%

Net income

$521.27M
EXEL annual net profit is $521.27 million

Net margin

24.04%
EXEL annual net profit margin is 24.04%

Expenses

Total expenses

$1.48B
EXEL annual total expenses is $1.48 billion

Operating expenses

$1.40B
EXEL annual total operating expenses is $1.40 billion

Cost of goods sold

$76.22M
EXEL annual cost of goods sold is $76.22 million

Selling, general & administrative expenses

$492.13M
EXEL annual SGA is $492.13 million

Depreciation and amortization

$28.80M
EXEL annual depreciation & amortization is $28.80 million

Interest expense

-
EXEL annual interest expense value is unknown

Income tax

$160.37M
EXEL annual income tax is $160.37 million

EBIT & EBITDA

EBIT

$689.95M
EXEL annual earnings before interest & taxes is $689.95 million

EBITDA

$718.75M
EXEL annual EBITDA is $718.75 million

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Total assets

$2.95B
EXEL annual total assets is $2.95 billion

Non current assets

$1.48B
EXEL annual long term assets is $1.48 billion

Current assets

$1.47B
EXEL annual total current assets is $1.47 billion

Cash and cash equivalents

$217.37M
EXEL annual cash & cash equivalents is $217.37 million

Accounts receivable

$265.44M
EXEL annual accounts receivable is $265.44 million

Inventory

$22.39M
EXEL annual inventory is $22.39 million

Liabilities

Total liabilities

$703.49M
EXEL annual total liabilities is $703.49 million

Long term liabilities

$299.72M
EXEL annual total long term liabilities is $299.72 million

Current liabilities

$403.77M
EXEL annual total current liabilities is $403.77 million

Accounts payable

$38.19M
EXEL annual accounts payable is $38.19 million

Debt

Total debt

$190.82M
EXEL annual total debt is $190.82 million

Total debt 1-year change

+0.46%
EXEL annual total debt is up +0.46% year-on-year

Long term debt

$190.82M
EXEL annual long term debt is $190.82 million

Short term debt

-
EXEL annual short term debt value is unknown

Equity & Capital

Shareholders equity

$2.24B
EXEL annual stockholders equity is $2.24 billion

Book value

$2.24B
EXEL annual book value is $2.24 billion

Retained earnings

-$98.65M
EXEL annual retained earnings is -$98.65 million

Working capital

$1.06B
EXEL annual working capital is $1.06 billion

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Cash from operations

$699.97M
EXEL annual cash flow from operations is $699.97 million

Cash from operations 1-year change

+110%
EXEL annual cash flow from operations is up +110% year-on-year

Cash from investing

-$116.78M
EXEL annual cash flow from investing activities is -$116.78 million

Cash from investing 1-year change

-333.25%
EXEL annual cash flow from investing activities is down -333.25% year-on-year

Cash from financing

-$628.81M
EXEL annual cash flow from financing activities is -$628.81 million

Cash from financing 1-year change

-15.16%
EXEL annual cash flow from financing activities is down -15.16% year-on-year

CAPEX

CAPEX

$66.19M
EXEL annual capital expenditures is $66.19 million

CAPEX 1-year change

-59.39%
EXEL annual capital expenditures is down -59.39% year-on-year

Free Cash Flow

Free cash flow

$633.79M
EXEL annual free cash flow is $633.79 million

Free cash flow 1-year change

+272.04%
EXEL annual free cash flow is up +272.04% year-on-year

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

Gross margin

96.49%
EXEL annual gross profit margin is 96.49%

Operating margin

31.81%
EXEL annual operating profit margin is 31.81%

Net margin

24.04%
EXEL annual net profit margin is 24.04%

ROA & ROE

ROA

17.70%
EXEL annual return on assets is 17.70%

ROE

23.13%
EXEL annual return on equity is 23.13%

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE ratio

20.56
EXEL price to earnings ratio is 20.56

PE ratio Sector rank

40.2%
EXEL price to earnings ratio is higher than 40.2% of companies in Healthcare sector

PB Ratio

PB ratio

4.54
EXEL price to book ratio is 4.54

PB ratio Sector rank

81.81%
EXEL price to book ratio is higher than 81.81% of companies in Healthcare sector

PS Ratio

PS ratio

4.70
EXEL price to sales ratio is 4.70

PS ratio Sector rank

65.13%
EXEL price to sales ratio is higher than 65.13% of companies in Healthcare sector

Enterprise value

Enterprise value

$10.16B
EXEL enterprise value is $10.16 billion

Enterprise value Sector rank

92.14%
EXEL enterprise value is higher than 92.14% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

14.14
EXEL EV/EBITDA is 14.14

EV/EBITDA Sector rank

87.29%
EXEL EV/EBITDA is higher than 87.29% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Current ratio

3.63
EXEL annual current ratio is 3.63

Quick ratio

3.58
EXEL annual quick ratio is 3.58

Leverage

Debt to equity

0.00
EXEL annual debt to equity ratio is 0.00

Interest coverage ratio

-
EXEL annual interest coverage ratio value is unknown

Risk & Stability

Piotroski F-Score

8
EXEL piotroski f-score is 8

Altman Z-Score

10.58
EXEL altman z-score is 10.58

Analyst ratings

Recent major analysts updates

Mar 27, 25 HC Wainwright & Co.
Buy
Mar 13, 25 RBC Capital
Outperform
Feb 24, 25 Wells Fargo
Equal-Weight
Feb 13, 25 HC Wainwright & Co.
Buy
Feb 13, 25 Barclays
Equal-Weight
Feb 12, 25 Stifel
Hold
Feb 12, 25 Stephens & Co.
Equal-Weight
Feb 12, 25 Piper Sandler
Overweight
Feb 12, 25 Guggenheim
Buy
Feb 12, 25 Citigroup
Buy

Institutional Ownership

Similar stocks

EHC logo
Encompass Health (EHC)
MRNA logo
Moderna (MRNA)
DOCS logo
Doximity (DOCS)
AVTR logo
Avantor (AVTR)
PEN logo
Penumbra (PEN)
GMED logo
Globus Medical (GMED)
NBIX logo
Neurocrine Biosciences (NBIX)
ATR logo
AptarGroup (ATR)
WBA logo
Walgreens Boots Alliance (WBA)
  • What is the ticker symbol for Exelixis?
  • Does Exelixis pay dividends?
  • What sector is Exelixis in?
  • What industry is Exelixis in?
  • What country is Exelixis based in?
  • When did Exelixis go public?
  • Is Exelixis in the S&P 500?
  • Is Exelixis in the NASDAQ 100?
  • Is Exelixis in the Dow Jones?
  • When was Exelixis's last earnings report?
  • When does Exelixis report earnings?
  • Should I buy Exelixis stock now?

What is the ticker symbol for Exelixis?

The ticker symbol for Exelixis is NASDAQ:EXEL

Does Exelixis pay dividends?

No, Exelixis does not pay dividends

What sector is Exelixis in?

Exelixis is in the Healthcare sector

What industry is Exelixis in?

Exelixis is in the Biotechnology industry

What country is Exelixis based in?

Exelixis is headquartered in United States

When did Exelixis go public?

Exelixis's initial public offering (IPO) was on April 17, 2000

Is Exelixis in the S&P 500?

No, Exelixis is not included in the S&P 500 index

Is Exelixis in the NASDAQ 100?

No, Exelixis is not included in the NASDAQ 100 index

Is Exelixis in the Dow Jones?

No, Exelixis is not included in the Dow Jones index

When was Exelixis's last earnings report?

Exelixis's most recent earnings report was on Feb 11, 2025

When does Exelixis report earnings?

The next expected earnings date for Exelixis is Apr 30, 2025

Should I buy Exelixis stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions
On this page